戻る Agenda
[Session 2] Non Clinical Proarrhythmic Risk Assessment
Session Chair(s)
Katsuyoshi Chiba, PHD
Senior Director and Head, Group III, Medicinal Safety Research Laboratories, R&D, Daiichi Sankyo Co., Ltd., Japan
Yasunari Kanda, PHD
Head of Division of Pharmacology, National Institute of Health Sciences, Japan
Speaker(s)
Atsushi Sugiyama, MD, PHD
Professor and Chairman, Department of Pharmacology, Toho University Faculty of Medicine, Japan
Keynote Lecture: Prediction and Quantification of Torsadogenic Potential Using Classical and New Assay Models
Gary Gintant, PHD
Research Fellow, AbbVie Inc., United States
CiPA: Validation Efforts and Update
Yasunari Kanda, PHD
Head of Division of Pharmacology, National Institute of Health Sciences, Japan
JiCSA Update: Proarrhythmia Risk Assessment Using Human iPS Cell-derived Cardiomyocytes
Keiichi Asakura, PHD
Senior Scientist, Pharmacokinetics and Safety Assessment Department, Nippon Shinyaku Co., Ltd., Japan
iSmart (investigation of in silico / in vitro model for Arrhythmogenic Risk Prediction) Update